“Proven Track Record of Transformational Leadership”

Equipped with more than three decades of experience, industry veteran Laurie Heilmann is leading Notable to new heights after joining the company in early 2020 as CEO. Heilmann has a proven track record of developing transformative strategies for biotech companies who are seeking significant change and does so by effectively energizing and mobilizing teams to reach beyond their potential. Heilmann’s high-touch approach has created a flexible culture that supports the challenges of working from home and enabling the team to remain connected and focused on advancing Notable’s platform during these challenging times.

Foster City, California-based Notable Labs, was founded in 2014 by Matt De Silva with the mission of redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers. Notable addresses this high unmet need with a clinically validated drug sensitivity platform to identify and advance novel therapeutic candidates. Notable’s testing platform combines machine learning, automation, and high-throughput screening directly on patient samples to predict responses to potential therapies and ultimately determine which therapies will be most effective for specific hematological cancers. The platform is fully customizable and built to scale across multiple disease types. This dramatically reduces the traditional drug development process, with the ultimate goal of getting new therapies to patients faster.

"Advancing data and diagnostics for precision medicine in hematological cancers "

In the prospective feasibility study titled, “Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms” published in Blood Advances (June 23, 2020; Volume 4, Issue 12), the authors attempted to determine if the drug sensitivity results from Notable’s platform could be returned to a tumor board within a clinically actionable timeframe (30 days) to inform personalized treatment recommendations. The study met its primary endpoint with the drug sensitivity data provided to the tumor board at a median turnaround time of 15 days. These data helped identify potentially useful drugs and drug combinations for myelodysplastic syndromes (MDS) patient’s refractory to standard therapies.

Today, Notable addresses several important unmet needs to optimize diagnostic testing for disease diagnosis, prognosis, and monitoring of hematological cancers. The platform enables data-driven decisions for drug development, critical for the next generation of superior hematological oncology therapies. “We want to change the way clinicians and prescribers select treatments for the millions of individuals suffering from hematological cancers. We recognize the need for more personalized approaches,” says Heilmann. Notable leverages fresh samples, machine learning, automation, and software to optimize drug sensitivity assays across a range of drug treatment classes.” Following their successful R&D summit last Fall, Heilmann has expanded the strategic roadmap to accelerate growth – including additional data and diagnostic product development over the next two years. With Heilmann’s leadership, strategic mindset and passion for developing internal talent, Notable is expected to grow into a leading, world class precision medicine company.IE